Prostate Cancer

One of the strongest mechanistic settings for apigenin, with Akt, NF-κB, EMT, and xenograft data.

Why this cancer is a plausible fit

Akt is constitutively active in many prostate cancers, including androgen-refractory and castration-resistant disease. NF-κB, particularly through IKKα, is also a major progression pathway.

Apigenin directly inactivates Akt and has been shown to bind IKKα, suppressing NF-κB/p65. Both mechanisms have been confirmed in mouse xenograft work.

Cell data

Multiple prostate cancer cell lines have been studied, including PC-3, DU145, LNCaP, and 22Rv1.

Reported effects include:

Akt dephosphorylation at Ser473 in a dose-dependent and time-dependent manner, leading to BAD activation and caspase-9-driven apoptosis
direct binding to IKKα, supported by in silico modelling and validated in vitro, with downstream NF-κB/p65 suppression
G2/M cell-cycle arrest
suppression of EMT markers and reduced migration and invasion in PC-3 M cells
cancer stem-cell suppression with re-sensitisation to chemotherapeutics
stronger apoptosis and lower migration with apigenin plus cisplatin than with either alone, linked to downregulation of BCL-2, survivin, and sharpin

Animal data

The in vivo prostate evidence is among the best-developed in the apigenin literature.

Animal studies show:

suppressed tumour growth in IKKα/NF-κB xenograft models with oral gavage dosing
confirmed Akt inactivation and apoptosis induction in PC-3 xenografts
marked reduction in metastasis to lung, liver, pancreas, spine, bone, and brain in intracardiac injection models using PC-3 M cells, with prolonged survival
inhibition of metastasis through SPOCK1 downregulation and Snail1/2 suppression

Human data

No completed prostate oncology trials have reported cancer outcomes with apigenin.

Preclinical research funding has supported chemoprevention work in this area, but that is not the same as clinical proof.

Clinical positioning

This is one of the strongest and most mechanistically developed settings in the apigenin literature.

It is especially relevant to castration-resistant prostate cancer, where Akt and NF-κB are major drivers. The in vivo data are among the best-quality in the field. No human trial data exist.

References

Shukla S and Gupta S. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study
Liu W, et al. A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer
Shukla S and Gupta S. Plant-derived flavone Apigenin: The small-molecule with promising activity against therapeutically resistant prostate cancer